http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103405754-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fd214dac3687284e1772c658563e7192 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-16 |
| filingDate | 2013-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee08983d56db8e82592689c65ea91f62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51ee380b706175bbb9b785e7ab85d94f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e62a2983a463ee870f7bed10818b9e3a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f3aabeb9f53a3181be4994b9d281c49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_096ac0ffb20d32e664e60d0d5d3bbd3c |
| publicationDate | 2015-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103405754-B |
| titleOfInvention | Solubilization technology for producing human fibrinogen |
| abstract | The invention relates to a solubilization technology for producing human fibrinogen. The solubilization technology comprises following main steps: (1) source plasma treatment; (2) dissolving and centrifuging of cryoprecipitate; (3) inactivation of viruses; (4) chromatography purification; (5) centrifugal separation; (6) dissolving of sediments; (7) degerming and filtering; (8) split charging and freeze drying. The solubilization technology has the advantages that the purity of the extracted product can be up to over 95%; the content of foreign protein is low; a lipid envelope virus and a non-lipid envelope virus can be effectively activated; the safety of the product is ensured; arginine hydrochloride and glycine are adopted as stabilizers; the product can be fully protected in a freeze-drying process; the temperature change of the product in the freeze-drying process is stable by prolonging the freeze-drying time (about 4-8 days, and about 3 days for general factories); a freeze-dried product with a uniform structure can be obtained; the solubility of the human fibrinogen is increased; the product is quick to dissolve after being re-dissolved; no highly visible denatured protein is generated. |
| priorityDate | 2013-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 53.